HK1029922A1 - Angiostatic agents and compositions for treating glc1a glaucoma - Google Patents

Angiostatic agents and compositions for treating glc1a glaucoma

Info

Publication number
HK1029922A1
HK1029922A1 HK01100647A HK01100647A HK1029922A1 HK 1029922 A1 HK1029922 A1 HK 1029922A1 HK 01100647 A HK01100647 A HK 01100647A HK 01100647 A HK01100647 A HK 01100647A HK 1029922 A1 HK1029922 A1 HK 1029922A1
Authority
HK
Hong Kong
Prior art keywords
compositions
angiostatic agents
treating
glc1a glaucoma
glaucoma
Prior art date
Application number
HK01100647A
Other languages
English (en)
Inventor
Abbot F Clark
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of HK1029922A1 publication Critical patent/HK1029922A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
HK01100647A 1997-12-19 2001-01-29 Angiostatic agents and compositions for treating glc1a glaucoma HK1029922A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/994,114 US5990099A (en) 1988-10-31 1997-12-19 Angiostatic agents and methods and compositions for controlling ocular hypertension
PCT/US1998/025913 WO1999032127A1 (fr) 1997-12-19 1998-12-07 Agents angiostatiques et compositions permettant de lutter contre l'hypertension intra-oculaire

Publications (1)

Publication Number Publication Date
HK1029922A1 true HK1029922A1 (en) 2001-04-20

Family

ID=25540297

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01100647A HK1029922A1 (en) 1997-12-19 2001-01-29 Angiostatic agents and compositions for treating glc1a glaucoma

Country Status (13)

Country Link
US (1) US5990099A (fr)
EP (1) EP1039912B1 (fr)
JP (1) JP2001526233A (fr)
AT (1) ATE221781T1 (fr)
AU (1) AU734436B2 (fr)
BR (1) BR9813684A (fr)
CA (1) CA2315829C (fr)
DE (1) DE69807115T2 (fr)
DK (1) DK1039912T3 (fr)
ES (1) ES2177112T3 (fr)
HK (1) HK1029922A1 (fr)
PT (1) PT1039912E (fr)
WO (1) WO1999032127A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041781A2 (fr) * 1999-12-09 2001-06-14 Alcon Universal Ltd. Inhibiteurs de proteine id pour le traitement de maladies oculaires
AU2001263324A1 (en) 2000-05-19 2001-12-03 Michael S. Berlin Laser delivery system and method of use for the eye
US8679089B2 (en) 2001-05-21 2014-03-25 Michael S. Berlin Glaucoma surgery methods and systems
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
EP1434786A4 (fr) * 2001-10-03 2009-03-25 Merck & Co Inc Androstane 17-beta-carboxamides en tant que modulateurs de recepteurs d'androgenes
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
PL1919290T3 (pl) * 2005-07-12 2014-06-30 Ampio Pharmaceuticals Inc Sposoby i produkty do leczenia chorób
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
AU2009221859B2 (en) 2008-03-05 2013-04-18 Alcon Inc. Methods and apparatus for treating glaucoma
CA2725008C (fr) * 2008-05-28 2017-09-05 Validus Biopharma, Inc. Modulateurs steroidiens non hormonaux de nf-.kappa.b pour le traitement d'une maladie
CA2765883A1 (fr) * 2009-06-22 2010-12-29 Dmi Acquisition Corp. Procedes et produits de traitement de maladies
DE202010017530U1 (de) 2009-06-22 2012-03-28 Dmi Acquisition Corp. Danazolverbindung zur Behandlung von Krankheiten
EP2451375B1 (fr) 2009-07-09 2018-10-03 Ivantis, Inc. Dispositif d'opérateur unique pour pose d'un implant oculaire
CN102481404B (zh) 2009-07-09 2014-03-05 伊万提斯公司 眼部植入物
US9198921B2 (en) 2010-04-05 2015-12-01 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
US20120283557A1 (en) 2011-05-05 2012-11-08 Berlin Michael S Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
US10617558B2 (en) 2012-11-28 2020-04-14 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
KR20150105355A (ko) 2012-12-19 2015-09-16 앰피오 파마슈티컬스 인코퍼레이티드 질병을 치료하기 위한 방법
US10709547B2 (en) 2014-07-14 2020-07-14 Ivantis, Inc. Ocular implant delivery system and method
EP3006453A1 (fr) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters et 17alpha, 21-diesters de cortexolone pour utilisation dans le traitement de tumeurs
WO2017004205A1 (fr) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. Modulateurs stéroïdiens non hormonaux de nf-κb pour le traitement de maladies
JP6837475B2 (ja) 2015-08-14 2021-03-03 イバンティス インコーポレイテッド 圧力センサを備えた眼用インプラントおよび送達システム
WO2017106517A1 (fr) 2015-12-15 2017-06-22 Ivantis, Inc. Implant vasculaire et système de pose
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
AU2022205382A1 (en) 2021-01-11 2023-06-22 Alcon Inc. Systems and methods for viscoelastic delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642355A (en) * 1984-02-24 1987-02-10 Otsuka Pharmaceutical Factory, Inc. Proline derivatives
US4863912A (en) * 1986-05-19 1989-09-05 New York Medical College Use of tetrahydrocortisol in glaucoma therapy
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
WO1991019731A1 (fr) * 1990-06-11 1991-12-26 The Upjohn Company Steroides qui inhibent l'angiogenese
CA2425841C (fr) * 1991-11-22 2006-01-10 Alcon Laboratories, Inc. Steroides angiostatiques
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5606043A (en) * 1994-11-03 1997-02-25 The Regents Of The University Of California Methods for the diagnosis of glaucoma

Also Published As

Publication number Publication date
US5990099A (en) 1999-11-23
ATE221781T1 (de) 2002-08-15
EP1039912B1 (fr) 2002-08-07
JP2001526233A (ja) 2001-12-18
AU734436B2 (en) 2001-06-14
DE69807115T2 (de) 2002-12-12
DE69807115D1 (de) 2002-09-12
WO1999032127A1 (fr) 1999-07-01
BR9813684A (pt) 2000-10-10
PT1039912E (pt) 2002-12-31
DK1039912T3 (da) 2002-10-28
EP1039912A1 (fr) 2000-10-04
AU1714299A (en) 1999-07-12
CA2315829C (fr) 2009-05-12
CA2315829A1 (fr) 1999-07-01
ES2177112T3 (es) 2002-12-01

Similar Documents

Publication Publication Date Title
HK1029922A1 (en) Angiostatic agents and compositions for treating glc1a glaucoma
DE69717312D1 (de) Intestinale absorption von nikotin für die behandlung von nikotinabhängigen zustanden
CY2473B1 (en) New phenanthridines.
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
MY114014A (en) Imidazole compounds, compositions and use
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
MY106484A (en) Combination therapy for phophylaxis and/or treatment of benign prostatic hyperplasia.
PL343904A1 (en) Compounds and methods for the inhibition of the expression of vcam-1
PL349028A1 (en) Cancer treatment composition and method using natural plant essential oils
UA41355C2 (uk) Засіб для лікування нейро-сніду
AU9016898A (en) Methods and compositions for treatment of restenosis
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
DE69629570D1 (de) 3'utr des menschliches prohibitin-gens
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
AU8020698A (en) Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain
PL314799A1 (en) Application of dimeticone in treating constipations
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
HK1039568A1 (en) Use of ap-1 activators to treat glaucoma and ocular hypertension.
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
AP9600780A0 (en) Process for the preparation of peroxetine hydrochloride anhydrate and its use as therapeutic agent.
AU7799898A (en) Compositions and methods for treating glaucoma
AU3643295A (en) Compositions of melatonin and analgetic agents and methods of use thereof
MX9709450A (es) Piridiniminil-1,2-benzoisoxazoles y -benzoisotiazoles como agentes antipsicoticos.
MX9709912A (es) Compuestos de imidazol, procedimiento para prepararlos y uso de los mismos.
TWI226833B (en) Pharmaceutical composition for inhibiting bone resorption

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111207